Recognizing dementia and Alzheimer's disease (AD) at an early stage is difficult to do. But that presymptomatic window, before obvious cognitive changes are evident, is thought to be the most effective time to prevent or treat disease. In fact, the FDA recently issued an update guidance advising drug companies to focus specifically upon that presymptomatic period.